{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:23:00Z","timestamp":1794428580314,"version":"4.9.1"},"reference-count":208,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Myeloid leukemia (ML) is a clonal malignant disease with abnormal hematopoietic stem cells. With the emergence of novel immunotherapies, such as CAR-T, therapeutic outcomes in ML patients have improved, while significant challenges persist, including severe adverse events and disease recurrence. Natural killer cells (NK cells) are \u201cnatural killers\u201d of the immune system that do not require antigen presentation and responsible for recognizing and destroying tumor cells. Some NK cells-based clinical experiments have been carried out and achieved remarkable results with lower side effects in ML. Crucially, within the ML microenvironment, NK cells frequently exhibit more severe functional exhaustion compared with T cells, characterized by impaired cytotoxicity, cytokine production, and proliferative capacity which limits anti-ML efficacy of NK cells. However, clinical studies utilizing NK cell-based therapies (e.g., adoptive transfer, CAR-NK cells) have demonstrated promising results with favorable safety profiles, underscoring their therapeutic potential. Therefore, developing more strategies based on NK cell is of great clinical significance for the treatment of ML. In this review, we systematically analysed the relationship between ML and NK cells, aiming to propose more novel protocols for NK cell expansion and persistence enhancement, establish evidence-based guidelines for next-generation NK cell-based immunotherapies in ML treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1621885","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T05:25:25Z","timestamp":1752470725000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["NK cell-based immunotherapy strategies for myeloid leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Lin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0260-3","article-title":"Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis","volume":"20","author":"Yamashita","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.217034","article-title":"The -7 chromosomal abnormalities with signs of myelodysplasia in chronic myeloid leukemia as a major red signal","volume":"104","author":"Cayssials","year":"2019","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.11.2982.2982","article-title":"Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy","volume":"78","author":"Rubin","year":"1991","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/modpathol.2012.29","article-title":"Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia","volume":"25","author":"Duncavage","year":"2012","journal-title":"Mod Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159579","article-title":"Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia","volume":"132","author":"Rutella","year":"2022","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a036244","article-title":"PTEN in regulating hematopoiesis and leukemogenesis","volume":"10","author":"Wu","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.03.001","article-title":"Multilevel targeting of hematopoietic stem cell self-renewal, differentiation and apoptosis for leukemia therapy","volume":"122","author":"Tsiftsoglou","year":"2009","journal-title":"Pharmacol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00355-z","article-title":"Leukaemia: a model metastatic disease","volume":"21","author":"Whiteley","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1148\/rg.2019180069","article-title":"Leukemic involvement in the thorax","volume":"39","author":"Shroff","year":"2019","journal-title":"Radiographics"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2021.04.003","article-title":"Update on lymphoblastic leukemia\/lymphoma","volume":"41","author":"Luca","year":"2021","journal-title":"Clin Lab Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24862","article-title":"Adult acute lymphoblastic leukemia: concepts and strategies","volume":"116","author":"Faderl","year":"2010","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-017-0450-y","article-title":"Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia","volume":"10","author":"Quijada-Alamo","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.05.001","article-title":"Targeting the tumor microenvironment of leukemia and lymphoma","volume":"5","author":"Hopken","year":"2019","journal-title":"Trends Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-3-030-49270-0_4","article-title":"NK cells in the tumor microenvironment","volume":"1273","author":"Guillerey","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41392-025-02228-5","article-title":"Overexpressing natural killer group 2 member A drives natural killer cell exhaustion in relapsed acute myeloid leukemia","volume":"10","author":"Xie","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101819-074948","article-title":"Natural killer cells: from innate to adaptive features","volume":"39","author":"Mujal","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-023-01428-2","article-title":"The role of exhausted natural killer cells in the immunopathogenesis and treatment of leukemia","volume":"22","author":"Barshidi","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15932","article-title":"Single-cell RNA-seq reveals a microenvironment and an exhaustion state of T\/NK cells in acute myeloid leukemia","volume":"114","author":"Zhang","year":"2023","journal-title":"Cancer Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108587","article-title":"Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages","volume":"106","author":"Ebrahimiyan","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"Ebiomedicine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-022-01243-1","article-title":"A four-stage model for murine natural killer cell development in vivo","volume":"15","author":"Ma","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00709-016-1016-5","article-title":"Axl signaling induces development of natural killer cells in vitro and in vivo","volume":"254","author":"Kim","year":"2017","journal-title":"Protoplasma"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1038\/s41467-018-06182-5","article-title":"Lin(-)CCR2(+) hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade","volume":"9","author":"Flores","year":"2018","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.610789","article-title":"Transcription factors associated with IL-15 cytokine signaling during NK cell development","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-00715-6","article-title":"mTORC1 and mTORC2 coordinate early NK cell development by differentially inducing E4BP4 and T-bet","volume":"28","author":"Li","year":"2021","journal-title":"Cell Death Differ"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.2006529","article-title":"CD122-targeted interleukin-2 and alphaPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation","volume":"10","author":"Reyes","year":"2021","journal-title":"Oncoimmunology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-298901","article-title":"Unique progenitors in mouse lymph node develop into CD127+ NK cells: thymus-dependent and thymus-independent pathways","volume":"117","author":"Luther","year":"2011","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910530524","article-title":"Expression of integrins and other adhesion molecules on NK cells; impact of IL-2 on short- and long-term cultures","volume":"53","author":"Maenpaa","year":"1993","journal-title":"Int J Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.imlet.2012.04.014","article-title":"Chemokines and NK cells: regulators of development, trafficking and functions","volume":"145","author":"Bernardini","year":"2012","journal-title":"Immunol Lett"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aai9062","article-title":"In silico modeling identifies CD45 as a regulator of IL-2 synergy in the NKG2D-mediated activation of immature human NK cells","volume":"10","author":"Mukherjee","year":"2017","journal-title":"Sci Signal"},{"key":"B39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.immuni.2011.11.016","article-title":"The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation","volume":"36","author":"Gordon","year":"2012","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0666","article-title":"Donor lymphocyte-derived natural killer cells control MHC class I-negative melanoma","volume":"8","author":"Dang","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-219881","article-title":"Fibronectin maintains survival of mouse natural killer (NK) cells via CD11b\/Src\/beta-catenin pathway","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1038\/s41467-019-13032-5","article-title":"Synergized regulation of NK cell education by NKG2A and specific Ly49 family members","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000613","article-title":"Evidence for prescribed NK cell Ly-49 developmental pathways in mice","volume":"206","author":"Millan","year":"2021","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/11.8.1239","article-title":"Natural killing of MHC class I(-) lymphoblasts by NK cells from long-term bone marrow culture requires effector cell expression of Ly49 receptors","volume":"11","author":"Lindberg","year":"1999","journal-title":"Int Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.immuni.2005.01.013","article-title":"A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells","volume":"22","author":"Freud","year":"2005","journal-title":"Immunity"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.11.004","article-title":"Hematopoietic stem cell niches produce lineage-instructive signals to control multipotent progenitor differentiation","volume":"45","author":"Cordeiro","year":"2016","journal-title":"Immunity"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132398","article-title":"The transcription factor E4bp4\/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression","volume":"211","author":"Male","year":"2014","journal-title":"J Exp Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200106)31:6<1900::aid-immu1900>3.0.co;2-m","article-title":"Identification of committed NK cell progenitors in adult murine bone marrow","volume":"31","author":"Rosmaraki","year":"2001","journal-title":"Eur J Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.06.007","article-title":"Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue","volume":"32","author":"Hughes","year":"2010","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/LVT.0000000000000139","article-title":"Immature and activated phenotype of blood NK cells is associated with acute rejection in adult liver transplant","volume":"29","author":"Song","year":"2023","journal-title":"Liver Transpl"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.912961","article-title":"Decreased CD57 expression of natural killer cells enhanced cytotoxicity in patients with primary sclerosing cholangitis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379693","article-title":"Human NK cells at early stages of differentiation produce CXCL8 and express CD161 molecule that functions as an activating receptor","volume":"119","author":"Montaldo","year":"2012","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502570","article-title":"Human CD56bright NK cells: an update","volume":"196","author":"Michel","year":"2016","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4049\/jimmunol.179.1.89","article-title":"CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts","volume":"179","author":"Chan","year":"2007","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02078","article-title":"Human NK cell development: one road or many","volume":"10","author":"Cichocki","year":"2019","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02482-2","article-title":"CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to gamma(c) cytokine stimulation via PI3K\/mTOR axis","volume":"69","author":"Capuano","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1183788","article-title":"Inhibitory NKG2A(+) and absent activating NKG2C(+) NK cell responses are associated with the development of EBV(+) lymphomas","volume":"14","author":"Vietzen","year":"2023","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-022-01058-z","article-title":"Natural killer cell homing and trafficking in tissues and tumors: from biology to application","volume":"7","author":"Ran","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200008","article-title":"The bone marrow functions as the central site of proliferation for long-lived NK cells","volume":"189","author":"van Helden","year":"2012","journal-title":"J Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.711621","article-title":"Activation of ADAM17 by IL-15 limits human NK cell proliferation","volume":"12","author":"Mishra","year":"2021","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.647358","article-title":"Natural killer cell integrins and their functions in tissue residency","volume":"12","author":"Shannon","year":"2021","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s10517-012-1650-7","article-title":"Effects of L-selectin stimulation of the expression of chemokine receptor CXCR4 on NK cells of healthy donors and tumor patients","volume":"153","author":"Perfilyeva","year":"2012","journal-title":"Bull Exp Biol Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1034\/j.1398-9995.2003.t01-1-23697.x","article-title":"Decreased intercellular adhesion molecule-1 (CD54) and L-selectin (CD62L) expression on peripheral blood\u00a0natural killer cells in asthmatic children with acute exacerbation","volume":"58","author":"Lin","year":"2003","journal-title":"Allergy"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173716","article-title":"CCR5 drives NK cell-associated airway damage in pulmonary ischemia-reperfusion injury","volume":"8","author":"Santos","year":"2023","journal-title":"JCI Insight"},{"key":"B68","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cytogfr.2020.12.003","article-title":"Chemokine networks modulating natural killer cell trafficking to solid tumors","volume":"59","author":"Yao","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00012","article-title":"Differential chemotactic receptor requirements for NK cell subset trafficking into bone marrow","volume":"4","author":"Bernardini","year":"2013","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-013-8400-0","article-title":"NK cell trafficking in health and autoimmunity: a comprehensive review","volume":"47","author":"Peng","year":"2014","journal-title":"Clin Rev Allergy Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-106203","article-title":"CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets","volume":"111","author":"Bernardini","year":"2008","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6437057","article-title":"Research progress on NK cell receptors and their signaling pathways","volume":"2020","author":"Chen","year":"2020","journal-title":"Mediators Inflamm"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.622306","article-title":"The role of natural killer cells in autoimmune diseases","volume":"12","author":"Kucuksezer","year":"2021","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02456","article-title":"Transcriptional, epigenetic and pharmacological control of JAK\/STAT pathway in NK cells","volume":"10","author":"Scarno","year":"2019","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000873","article-title":"Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines","volume":"8","author":"Park","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2013.03.002","article-title":"Down regulation of TRAIL and FasL on NK cells by Cyclosporin A in renal transplantation patients","volume":"152","author":"Zhang","year":"2013","journal-title":"Immunol Lett"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1177\/1753425918800200","article-title":"When and how NK cell-induced programmed cell death benefits immunological protection against intracellular pathogen infection","volume":"24","author":"Belizario","year":"2018","journal-title":"Innate Immun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03217-1","article-title":"Natural killer cells and acute myeloid leukemia: promises and challenges","volume":"71","author":"Rahmani","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e18915","DOI":"10.7759\/cureus.18915","article-title":"Prognostics and clinical outcomes in patients diagnosed with acute myeloid leukemia (AML) in a teaching hospital","volume":"13","author":"Alsulami","year":"2021","journal-title":"Cureus"},{"key":"B80","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","article-title":"The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017","volume":"13","author":"Yi","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103607","article-title":"Diagnosis and treatment of therapy-related acute myeloid\u00a0leukemia","volume":"171","author":"Strickland","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.3390\/ijms23041968","article-title":"Straight to the point-the novel strategies to cure pediatric AML","volume":"23","author":"Lejman","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute\u00a0myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"key":"B84","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13059-023-03031-7","article-title":"Single-cell transcriptomics reveals multiple chemoresistant properties in leukemic stem and progenitor cells in pediatric AML","volume":"24","author":"Zhang","year":"2023","journal-title":"Genome Biol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215997","article-title":"Therapeutic inhibition of PPARalpha-HIF1alpha-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia","volume":"554","author":"Zhou","year":"2023","journal-title":"Cancer Lett"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.3390\/cells13161392","article-title":"Common driver mutations in AML: biological impact, clinical considerations, and treatment strategies","volume":"13","author":"Nong","year":"2024","journal-title":"Cells"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016033","article-title":"Proteomic and phosphoproteomic landscapes of acute myeloid leukemia","volume":"140","author":"Kramer","year":"2022","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.163","article-title":"Subtype-specific patterns of molecular mutations in acute myeloid leukemia","volume":"31","author":"Rose","year":"2017","journal-title":"Leukemia"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003605","article-title":"Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)","volume":"5","author":"Han","year":"2021","journal-title":"Blood Adv"},{"key":"B90","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41408-019-0241-5","article-title":"The ATRA-21 gene-expression model predicts retinoid sensitivity in CEBPA double mutant, t(8;21) and inv(16) AML patients","volume":"9","author":"Bolis","year":"2019","journal-title":"Blood Cancer J"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02217-7","article-title":"Targeting the innate immune system in pediatric and adult AML","volume":"38","author":"Perzolli","year":"2024","journal-title":"Leukemia"},{"key":"B92","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/gene.2014.58","article-title":"Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia","volume":"16","author":"Baragano","year":"2015","journal-title":"Genes Immun"},{"key":"B93","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/eji.202048945","article-title":"Immunity in acute myeloid leukemia: Where the immune response and targeted therapy meet","volume":"52","author":"Fink","year":"2022","journal-title":"Eur J Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000792","article-title":"Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival","volume":"4","author":"Bruck","year":"2020","journal-title":"Blood Adv"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Transl Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"5944","DOI":"10.1038\/s41598-021-85122-8","article-title":"Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression","volume":"11","author":"Weickert","year":"2021","journal-title":"Sci Rep"},{"key":"B97","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s13287-021-02444-0","article-title":"Bone marrow-derived mesenchymal stem\/stromal cells in patients with acute myeloid leukemia reveal transcriptome alterations and deficiency in cellular vitality","volume":"12","author":"Zhang","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03732-0","article-title":"Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy","volume":"119","author":"Xu","year":"2024","journal-title":"Int J Hematol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1172\/JCI169245","article-title":"Alkynyl nicotinamides show antileukemic activity in drug-resistant acute myeloid leukemia","volume":"134","author":"Ramdas","year":"2024","journal-title":"J Clin Invest"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.10.146","article-title":"Longitudinal preclinical imaging characterizes extracellular drug accumulation after radiation therapy in the healthy and leukemic bone marrow vascular microenvironment","volume":"112","author":"Brooks","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B101","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33477","article-title":"Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach","volume":"127","author":"Kantarjian","year":"2021","journal-title":"Cancer"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.3390\/cancers15112944","article-title":"CAR-T cells immunotherapies for the treatment of acute myeloid leukemia-recent advances","volume":"15","author":"Zarychta","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282030","article-title":"Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)","volume":"108","author":"Richard-Carpentier","year":"2023","journal-title":"Haematologica"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.656218","article-title":"Immunotherapy in acute myeloid leukemia: where we stand","volume":"11","author":"Isidori","year":"2021","journal-title":"Front Oncol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.3390\/cancers13174364","article-title":"Paving the way for immunotherapy in pediatric acute myeloid leukemia: current knowledge and the way forward","volume":"13","author":"Koedijk","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02357","article-title":"Natural killer cells in myeloid Malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells","volume":"10","author":"Carlsten","year":"2019","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11154","article-title":"Repression of GSK3 restores NK cell cytotoxicity in AML patients","volume":"7","author":"Parameswaran","year":"2016","journal-title":"Nat Commun"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018079","article-title":"Restoring NK cell functions in AML relapse","volume":"140","author":"Kim","year":"2022","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3548","article-title":"Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)","volume":"105","author":"Pende","year":"2005","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.03.004","article-title":"Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic Malignancies","volume":"16","author":"Stringaris","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"key":"B112","doi-asserted-by":"publisher","first-page":"123r","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115718","article-title":"Cytokine-Induced Memory-Like NK Cells: Emerging strategy for AML immunotherapy","volume":"168","author":"Bakhtiyaridovvombaygi","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-022-00660-2","article-title":"Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia","volume":"12","author":"Albinger","year":"2022","journal-title":"Blood Cancer J"},{"key":"B116","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41408-024-01050-6","article-title":"Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody","volume":"14","author":"Stefanczyk","year":"2024","journal-title":"Blood Cancer J"},{"key":"B117","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/cancers15010117","article-title":"CAR-NK as a rapidly developed and efficient immunotherapeutic strategy against cancer","volume":"15","author":"Wlodarczyk","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01435-3","article-title":"CAR-NK cell therapy for hematological Malignancies: recent updates from ASH 2022","volume":"16","author":"Huang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","article-title":"Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia","volume":"15","author":"Caruso","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01065-5","article-title":"A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells","volume":"35","author":"Arvindam","year":"2021","journal-title":"Leukemia"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003099","article-title":"B7-H3 in acute myeloid leukemia: From prognostic biomarker to immunotherapeutic target","volume":"137","author":"Tan","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B123","doi-asserted-by":"publisher","first-page":"p4","DOI":"10.1126\/scitranslmed.adp0004","article-title":"BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML","volume":"16","author":"Kumar","year":"2024","journal-title":"Sci Transl Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.791986","article-title":"Natural killer cell receptor repertoire is comparable amongst newly diagnosed acute myeloid leukemia of different French-American-British subtypes, risk categories and chemosensitivities","volume":"55","author":"Ho","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500262","article-title":"Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion","volume":"195","author":"Khaznadar","year":"2015","journal-title":"J Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1515\/med-2022-0551","article-title":"NK-cell dysfunction of acute myeloid leukemia in relation to the renin-angiotensin system and neurotransmitter genes","volume":"17","author":"Turk","year":"2022","journal-title":"Open Med (Wars)"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s42003-023-05433-6","article-title":"Cellular senescence triggers intracellular acidification and lysosomal pH alkalinized via ATP6AP2 attenuation in breast cancer cells","volume":"6","author":"Li","year":"2023","journal-title":"Commun Biol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41420-022-00967-w","article-title":"ATP6AP2 knockdown in cardiomyocyte deteriorates heart function via compromising autophagic flux and NLRP3 inflammasome activation","volume":"8","author":"Li","year":"2022","journal-title":"Cell Death Discov"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803523","article-title":"Regulation of NK cell function by human granulocyte arginase","volume":"182","author":"Oberlies","year":"2009","journal-title":"J Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00574-8","article-title":"Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia","volume":"18","author":"Crinier","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3390\/cells12040633","article-title":"A killer disarmed: natural killer cell impairment in myelodysplastic syndrome","volume":"12","author":"Arellano-Ballestero","year":"2023","journal-title":"Cells"},{"key":"B132","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12964-022-00985-2","article-title":"Bone marrow mesenchymal stem cells regulate the dysfunction of NK cells via the T cell immunoglobulin and ITIM domain in patients with myelodysplastic syndromes","volume":"20","author":"Liu","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02126-1","article-title":"Harnessing upregulated E-selectin while enhancing SDF-1alpha sensing redirects infused NK cells to the AML-perturbed bone marrow","volume":"38","author":"Sanz-Ortega","year":"2024","journal-title":"Leukemia"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2020459118","article-title":"High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a\u00a0subgroup with adverse clinical outcome","volume":"118","author":"Chretien","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01626-2","article-title":"Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123","volume":"41","author":"Gauthier","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molimm.2017.11.003","article-title":"Characteristics of NK cells from leukemic microenvironment in MLL-AF9 induced acute myeloid leukemia","volume":"93","author":"Yang","year":"2018","journal-title":"Mol Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.751834","article-title":"Acute myeloid leukemia epigenetic immune escape from nature killer cells by ICAM-1","volume":"11","author":"Xiao","year":"2021","journal-title":"Front Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-1-13","article-title":"Immune evasion in acute myeloid leukemia: current concepts and future directions","volume":"1","author":"Teague","year":"2013","journal-title":"J Immunother Cancer"},{"key":"B140","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12943-023-01889-6","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy","volume":"22","author":"Sauerer","year":"2023","journal-title":"Mol Cancer"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.87","article-title":"Natural killer cell immune escape in acute myeloid leukemia","volume":"26","author":"Lion","year":"2012","journal-title":"Leukemia"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0202","article-title":"Recent advances in immune-based therapies for acute myeloid leukemia","volume":"5","author":"Restelli","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103164","article-title":"Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways","volume":"157","author":"Taghiloo","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112059","article-title":"NK cell defects: implication in acute myeloid leukemia","volume":"14","author":"D\u2019Silva","year":"2023","journal-title":"Front Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00475","article-title":"Immune biology of acute myeloid leukemia: implications for immunotherapy","volume":"39","author":"Khaldoyanidi","year":"2021","journal-title":"J Clin Oncol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-020-01069-1","article-title":"New strategies to treat AML: novel insights into AML survival pathways and combination therapies","volume":"35","author":"Nair","year":"2021","journal-title":"Leukemia"},{"key":"B147","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"B148","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12185-024-03778-0","article-title":"Evolution of natural killer cell-targeted therapy for acute myeloid leukemia","volume":"120","author":"Kaito","year":"2024","journal-title":"Int J Hematol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.4.1737","article-title":"Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate","volume":"97","author":"Era","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05966-8","article-title":"Identification of a novel cryptic variant chromosomal rearrangement involving 9q34, 22q11.2, and 5q22 resulting in ins(9;22) and t(5;22) in chronic myeloid leukemia: a case report","volume":"103","author":"Ahmad","year":"2024","journal-title":"Ann Hematol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0490-0","article-title":"Chronic myeloid leukemia stem cells","volume":"33","author":"Houshmand","year":"2019","journal-title":"Leukemia"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.4065\/81.4.553","article-title":"Atypical myeloproliferative disorders: diagnosis and management","volume":"81","author":"Tefferi","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"B153","doi-asserted-by":"publisher","first-page":"7093","DOI":"10.3390\/ijms22137093","article-title":"Targeting leukemic stem cells in chronic myeloid leukemia: is it worth the effort","volume":"22","author":"Soverini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.26","article-title":"Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells","volume":"29","author":"Riether","year":"2015","journal-title":"Leukemia"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.106273","article-title":"Role of cancer immunology in chronic myelogenous leukemia","volume":"88","author":"Ureshino","year":"2020","journal-title":"Leuk Res"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35038","article-title":"Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019","volume":"129","author":"Sasaki","year":"2023","journal-title":"Cancer"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.05.006","article-title":"Generic imatinib in chronic myeloid leukemia treatment: long-term follow-up","volume":"19","author":"Cojbasic","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-024-01003-y","article-title":"BCAT1 contributes to the development of TKI-resistant CML","volume":"48","author":"Jiang","year":"2024","journal-title":"Cell Oncol (Dordr)"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0983-x","article-title":"Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy","volume":"34","author":"Venkataraman","year":"2020","journal-title":"Leukemia"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0824-y","article-title":"A novel chimeric antigen receptor redirecting T-cell specificity towards CD26(+) cancer cells","volume":"35","author":"Zhou","year":"2021","journal-title":"Leukemia"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1012981","article-title":"Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase","volume":"13","author":"Cui","year":"2022","journal-title":"Front Immunol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/cancers16010090","article-title":"NK3.3-derived extracellular vesicles penetrate and selectively kill treatment-resistant tumor cells","volume":"16","author":"McCune","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B167","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40164-022-00289-8","article-title":"Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D\/NKG2D-L pathway to kill CML cells with or without T315I mutation","volume":"11","author":"Du","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801137","article-title":"CD137 (4-1BB) engagement fine-tunes synergistic IL-15- and IL-21-driven NK cell proliferation","volume":"203","author":"Vidard","year":"2019","journal-title":"J Immunol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3390\/cells9040811","article-title":"Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK cells with Enhanced Antitumor Activity","volume":"9","author":"Oberoi","year":"2020","journal-title":"Cells"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0151","article-title":"Sequential exposure to IL21 and IL15 during human natural killer cell expansion optimizes yield and function","volume":"11","author":"Zhang","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-024-03761-8","article-title":"Current insights into CAR T-cell-based therapies for myelodysplastic syndrome","volume":"41","author":"Gandhi","year":"2024","journal-title":"Pharm Res"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2015.01.009","article-title":"Multiple effects of IL-21 on human NK cells in ex vivo expansion","volume":"220","author":"Li","year":"2015","journal-title":"Immunobiology"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1309010","article-title":"Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model","volume":"14","author":"Imeri","year":"2023","journal-title":"Front Immunol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1186\/s12885-021-08590-1","article-title":"A phase I\/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer","volume":"21","author":"Yu","year":"2021","journal-title":"BMC Cancer"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.03.312","article-title":"NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors","volume":"21","author":"Park","year":"2019","journal-title":"Cytotherapy"},{"key":"B177","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.3390\/ijms20194693","article-title":"EGFR-specific tyrosine kinase inhibitor modifies NK cell-mediated antitumoral activity against ovarian cancer cells","volume":"20","author":"Mallmann-Gottschalk","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02074-w","article-title":"Single-cell analysis of immune recognition in chronic myeloid leukemia\u00a0patients following tyrosine kinase inhibitor discontinuation","volume":"38","author":"Huuhtanen","year":"2024","journal-title":"Leukemia"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9531549","article-title":"Increased expression of TIGIT\/CD57 in peripheral blood\/bone marrow NK cells in patients with chronic myeloid leukemia","volume":"2020","author":"Yao","year":"2020","journal-title":"BioMed Res Int"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21349","article-title":"Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes","volume":"90","author":"Aggarwal","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.6.2279.bloodjournal8862279","article-title":"CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis","volume":"88","author":"Pierson","year":"1996","journal-title":"Blood"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1172","article-title":"BCR\/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs)","volume":"101","author":"Chiorean","year":"2003","journal-title":"Blood"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.2.643","article-title":"The BCR\/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients","volume":"168","author":"Nakajima","year":"2002","journal-title":"J Immunol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.5.1961","article-title":"Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine","volume":"96","author":"Mellqvist","year":"2000","journal-title":"Blood"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0512257","article-title":"Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent inactivation and cell death in lymphocytes","volume":"93","author":"Aurelius","year":"2013","journal-title":"J Leukoc Biol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.172216","article-title":"Maternal CXCR4 deletion results in placental defects and pregnancy loss mediated by immune dysregulation","volume":"8","author":"Lyu","year":"2023","journal-title":"JCI Insight"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14910","article-title":"Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance","volume":"24","author":"Herrmann","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0479","article-title":"The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions","volume":"106","author":"Sconocchia","year":"2005","journal-title":"Blood"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017295","article-title":"A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia","volume":"141","author":"Krishnan","year":"2023","journal-title":"Blood"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-1052","article-title":"TGFbeta and CIS inhibition overcomes NK-cell suppression to restore antitumor immunity","volume":"10","author":"Souza-Fonseca-Guimaraes","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1473139","article-title":"The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy","volume":"15","author":"Decroos","year":"2024","journal-title":"Front Immunol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1241600","article-title":"In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy","volume":"14","author":"Sanchez","year":"2023","journal-title":"Front Immunol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02587","article-title":"Effect of age on NK cell compartment in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors","volume":"9","author":"Rodrigues-Santos","year":"2018","journal-title":"Front Immunol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02809-5","article-title":"Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation","volume":"111","author":"Ureshino","year":"2020","journal-title":"Int J Hematol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772408","article-title":"Inflammatory cytokines shape an altered immune response during myeloid Malignancies","volume":"12","author":"Camacho","year":"2021","journal-title":"Front Immunol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune effector recovery in chronic myeloid leukemia and treatment-free remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front Immunol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"key":"B198","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40164-024-00481-y","article-title":"Targeting natural killer cells: from basic biology to clinical application in hematologic Malignancies","volume":"13","author":"Shang","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.11.013","article-title":"Targeting HLA-DR loss in hematologic Malignancies with an inhibitory chimeric antigen receptor","volume":"30","author":"Fei","year":"2022","journal-title":"Mol Ther"},{"key":"B200","doi-asserted-by":"publisher","first-page":"e70210","DOI":"10.1002\/iid3.70210","article-title":"CAR-NK, a splendid strategy for cancer, especially for gynecologic tumor","volume":"13","author":"Cao","year":"2025","journal-title":"Immun Inflammation Dis"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1550652","article-title":"Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells","volume":"16","author":"Guo","year":"2025","journal-title":"Front Immunol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112523","article-title":"Chimeric antigen receptor NK-92 cell function is modulated by HLA class I expression of target cells","volume":"28","author":"Stransky","year":"2025","journal-title":"iScience"},{"key":"B203","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s43018-025-00934-1","article-title":"CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant","volume":"6","author":"Ikeda","year":"2025","journal-title":"Nat Cancer"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117024","article-title":"CAR-NK cell therapy in AML: Current treatment, challenges, and advantage","volume":"177","author":"Bahramloo","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B205","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12943-024-02151-3","article-title":"CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside","volume":"23","author":"Zhu","year":"2024","journal-title":"Mol Cancer"},{"key":"B206","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov"},{"key":"B207","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1038\/s41467-025-58662-0","article-title":"Natural killer cells\u2019 functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes","volume":"16","author":"Rodriguez-Sevilla","year":"2025","journal-title":"Nat Commun"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101889","article-title":"CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1621885\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T05:25:26Z","timestamp":1752470726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1621885\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":208,"alternative-id":["10.3389\/fimmu.2025.1621885"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1621885","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"article-number":"1621885"}}